PBYI - Puma Bio: Sifting Through The Q4 Earnings Report
Puma Biotechnology (PBYI) recently publicized their Q4/2019 earnings that revealed a strong beat in both EPS and revenue. Puma reported total revenue for the fourth quarter of 2019 of $62.9M. Total product revenue consisted of license revenue of $4M, royalty revenue of $0.2M and net sales of NERLYNX of $58.7M. Net sales of $58.7M in the fourth quarter of 2019 represented a 9.7% increase from the $53.5M in net sales reported in the third quarter of 2019.
I intend to review the company Q4 earnings and the company’s efforts to maximize NERLYNX commercial